Thermoresponsive Polyoxazolines as Vectors for Transfection of Nucleic Acids.
Poly(2-oxazoline)s
gene delivery
mesoglobules
non-viral vectors
polyethyleneimine
Journal
Polymers
ISSN: 2073-4360
Titre abrégé: Polymers (Basel)
Pays: Switzerland
ID NLM: 101545357
Informations de publication
Date de publication:
06 Nov 2020
06 Nov 2020
Historique:
received:
13
10
2020
revised:
01
11
2020
accepted:
03
11
2020
entrez:
11
11
2020
pubmed:
12
11
2020
medline:
12
11
2020
Statut:
epublish
Résumé
Poly(2-oxazoline)s (POx) are an attractive platform for the development of non-viral gene delivery systems. The combination of POx moieties, exhibiting excellent biocompatibility, with DNA-binding polyethyleneimine (PEI) moieties into a single copolymer chain is a promising approach to balance toxicity and transfection efficiency. The versatility of POx in terms of type of substituent, copolymer composition, degree of polymerization, degree of hydrolysis, and chain architecture, as well as the introduction of stimuli-responsive properties, provides opportunities to finely tune the copolymer characteristics and physicochemical properties of the polyplexes to increase the biological performance. An overview of the current state of research in the POx-PEI-based gene delivery systems focusing particularly on thermosensitive POx is presented in this paper.
Identifiants
pubmed: 33171983
pii: polym12112609
doi: 10.3390/polym12112609
pmc: PMC7694630
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Eur J Pharm Biopharm. 2018 Dec;133:112-121
pubmed: 30308239
Biomacromolecules. 2018 Jul 9;19(7):2870-2879
pubmed: 29698602
Eur Polym J. 2017 Mar;88:679-688
pubmed: 28713172
Angew Chem Int Ed Engl. 2009;48(43):7978-94
pubmed: 19768817
Nature. 2002 Nov 14;420(6912):116-8
pubmed: 12432357
Hum Gene Ther. 2001 May 20;12(8):861-70
pubmed: 11387052
Clin Med Res. 2006 Sep;4(3):218-27
pubmed: 16988102
Expert Opin Drug Deliv. 2013 Feb;10(2):215-28
pubmed: 23252504
Nature. 1992 Jun 11;357(6378):455-60
pubmed: 1608446
Eur J Pharm Biopharm. 2005 Jul;60(2):247-66
pubmed: 15939236
Nat Biotechnol. 2015 Mar;33(3):217-8
pubmed: 25748892
Bioconjug Chem. 2003 May-Jun;14(3):581-7
pubmed: 12757382
Pharm Res. 1999 Aug;16(8):1273-9
pubmed: 10468031
Adv Drug Deliv Rev. 2007 Dec 22;59(15):1504-20
pubmed: 17904246
Pharmacol Ther. 2006 Dec;112(3):630-48
pubmed: 16815554
J Mater Sci Mater Med. 2015 Apr;26(4):157
pubmed: 25783502
Anal Bioanal Chem. 2009 Jan;393(1):367-76
pubmed: 18759104
Biomacromolecules. 2016 Nov 14;17(11):3580-3590
pubmed: 27723983
J Phys Chem B. 2009 Oct 22;113(42):13910-6
pubmed: 19778003
AAPS J. 2009 Dec;11(4):671-81
pubmed: 19834816
Mol Pharm. 2013 Nov 4;10(11):4082-98
pubmed: 24093932
J Mater Chem B. 2017 Feb 14;5(6):1258-1274
pubmed: 32263594
Nanomedicine. 2011 Aug;7(4):445-53
pubmed: 21220051
J Control Release. 2001 Jun 15;73(2-3):391-9
pubmed: 11516514
Gene Ther. 2003 Jun;10(11):955-63
pubmed: 12756416
Biotechnol Lett. 2012 Jan;34(1):19-28
pubmed: 22009568
Chem Commun (Camb). 2008 Nov 30;(44):5758-60
pubmed: 19009072
Soft Matter. 2007 Mar 20;3(4):430-431
pubmed: 32900061
Nat Biotechnol. 2000 Jan;18(1):33-7
pubmed: 10625387
J Control Release. 2011 Oct 30;155(2):248-61
pubmed: 21621570
Int J Nanomedicine. 2013;8:4091-102
pubmed: 24204139
Ther Deliv. 2011 Apr;2(4):493-521
pubmed: 22826857
Gene Ther. 2003 Sep;10(20):1721-7
pubmed: 12939638
J Mater Sci Mater Med. 2011 Jul;22(7):1725-34
pubmed: 21604137
Macromol Biosci. 2018 Apr;18(4):e1700349
pubmed: 29488321
Bioconjug Chem. 2006 May-Jun;17(3):781-6
pubmed: 16704218
J Control Release. 1999 Aug 5;60(2-3):149-60
pubmed: 10425321
Small. 2013 Jun 24;9(12):2034-44
pubmed: 23630123
Curr Opin Biotechnol. 2010 Oct;21(5):640-5
pubmed: 20674331
Macromol Rapid Commun. 2010 Mar 16;31(6):511-25
pubmed: 21590935
Macromol Rapid Commun. 2012 Oct 15;33(19):1613-31
pubmed: 22865555
J Control Release. 2005 Jan 20;102(1):263-75
pubmed: 15653151
Bioimpacts. 2011;1(1):23-30
pubmed: 23678404